Michael J. McBreen - Feb 13, 2023 Form 4 Insider Report for INTEGRA LIFESCIENCES HOLDINGS CORP (IART)

Signature
/s/ Eric Schwartz; Attorney-in-Fact
Stock symbol
IART
Transactions as of
Feb 13, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 03:18 PM
Previous filing
Aug 3, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IART Common Stock Award $0 +1.47K +5.8% $0.00 26.8K Feb 13, 2023 Direct F1
transaction IART Common Stock Award $0 +1.01K +3.77% $0.00 27.8K Feb 13, 2023 Direct F2
transaction IART Common Stock Award $0 +1.68K +6.05% $0.00 29.4K Feb 13, 2023 Direct F2
transaction IART Common Stock Award $0 +1.92K +6.52% $0.00 31.4K Feb 13, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 13, 2020 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 34% of the shares will vest on March 13, 2023, the third anniversary of the grant date.
F2 On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 12, 2021 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2023, the second anniversary of the grant date.
F3 On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 11, 2022 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 11, 2023, the first anniversary of the grant date.